|Day's range||140.40 - 140.40|
Over time, Biogen (NASDAQ: BIIB) created a true success story. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. Now, though, Biogen may have found that new growth source.
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key Insights The projected fair value for Biogen is US$362 based on 2 Stage Free Cash Flow to Equity Biogen's US$265...